German drugmaker CureVac and GSK reached an agreement with BioNTech and Pfizer on Thursday to resolve a years-long patent ...

CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with Pfizer and ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

The intervention under investigation is GEN1056, a biological treatment administered via intravenous infusion. Its primary purpose is to evaluate safety and antitumor activity, with the ultimate goal ...

BioNTech also laid off 63 employees in June in conjunction with the discontinuation of its cell therapy manufacturing ...

Further evidence that US Department of Health and Human Services (HHS) secretary Robert F Kennedy Junior (RFK Jr) is willing ...

Victoria is cementing its position as a global hub for biotechnology and life sciences, with BioNTech establishing a state-of ...

BioNTech SE BNTX -0.15% Get Free Report reported a narrower loss for the second quarter on Monday. The company posted a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, versus a loss of ...

As part of a "strategic alignment" of its pipeline, BioNTech is laying off 90 workers in R&D and corporate roles across two sites in Maryland and Massachusetts, a spokesperson told Fierce. | As part ...

Clear Street raised the firm’s price target on BioNTech (BNTX) to $185 from $181 and keeps a Buy rating on the shares after updating the firm’s model to a year-end 2026 valuation following the company ...

Why it matters: In addition to ongoing clinical trial progress for BNT327, BioNTech was active on the business development ...